aHUS are we there yet?
Last summer, aHUS alliance’s Twitter Account featured the plight of a patient who, after a week in hospital, had been found…
aHUS Diagnosis Process – Report 2
The second article in the series about the aHUS Diagnosis Process has been published on the website today. Research made possible…
Living with aHUS- what would you say?
If asked by health policy decision makers, and with a 500 words limit, how would you answer the question "how does…
Good complement goes aHUS bad
OK, so HUS is caused by e.coli toxins and aHUS results from Complement dysregulation. Both are thrombotic microangiopathies. HUS is…
Ravulizumab is not quite eculizumab
Ravulizumab is becoming a treatment of choice for aHUS in countries where access is funded. Though eculizumab will still have a…
Call to action USA aHUS Patients
In Article 462 notice was given of a study to help USA rare disease patients in general. and aHUS patients in…
Withdrawal – need for a consensus
Article No. 457 Yet another article about the outcome of withdrawal of eculizumab treatment has appeared. It is not about a…
aHUS website refreshed
Article No. 456 From today the aHUS alliance Global Action website has a new look. Just over five years since it…
The final aHUS Awareness Day?
Article No. 455 Dr Carla Nester is well known to the hundreds of aHUS families in the USA, and elsewhere, who…
- Go to the previous page
- 1
- …
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- …
- 50
- Go to the next page